. Author manuscript; available in PMC: 2011 Jun 1.

Published in final edited form as: Cancer Prev Res (Phila). 2010 Apr 19;3(6):696–706. doi: 10.1158/1940-6207.CAPR-10-0076

Table 3.

Annual rates of noninvasive breast cancer and uterine disease/hysterectomy—NSABP STAR Trial (P-2)

Disease/uterine event type	Events, n		Rate per 1,000			RR^†	RR (95% CI)
Disease/uterine event type	Tamoxifen	Raloxifene	Tamoxifen	Raloxifene	Difference^*	RR^†	RR (95% CI)
Noninvasive breast cancer
DCIS	70	86	1.15	1.40	−0.25	1.22	0.88–1.69
LCIS	33	34	0.54	0.55	−0.01	1.02	0.61–1.70
Mixed	8	17	0.13	0.28	−0.15	2.11	0.86–5.64
Total	111	137	1.83	2.23	−0.40	1.22	0.95–1.59

Uterine disease and hysterectomy^‡
Invasive Cancer	65	37	2.25	1.23	1.02	0.55	0.36–0.83
Hyperplasia^§	126	25	4.40	0.84	3.56	0.19	0.12–0.29
Without atypia^§	104	21	3.63	0.70	2.93	0.19	0.11–0.31
With atypia^§	22	4	0.77	0.13	0.64	0.17	0.04–0.51
Hysterectomy during follow-up	349	162	12.08	5.41	6.67	0.45	0.37–0.54

Abbreviations, CI, confidence interval; DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in situ; NSABP STAR, National Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene; RR, risk ratio.

Rate in the tamoxifen group minus rate in the raloxifene group.

^†

Risk ratio for women in the raloxifene group compared with women in the tamoxifen group.

^‡

Women at risk were those with an intact uterus at entry (see Table 1).

^§

Among women not diagnosed with uterine cancer.